See more : UNISON METALS LTD (UNISON.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Apontis Pharma AG (APPH.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apontis Pharma AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- SHUEI YOBIKO Co., Ltd. (4678.T) Income Statement Analysis – Financial Results
- Orora Limited (ORRYY) Income Statement Analysis – Financial Results
- Entersoft S.A. (ENTER.AT) Income Statement Analysis – Financial Results
- NKK Switches Co., Ltd. (6943.T) Income Statement Analysis – Financial Results
- STS Holding S.A. (STH.WA) Income Statement Analysis – Financial Results
Apontis Pharma AG (APPH.DE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://apontis-pharma.de
About Apontis Pharma AG
Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 36.96M | 55.73M | 51.18M | 39.24M | 40.04M |
| Cost of Revenue | 13.79M | 20.74M | 17.40M | 14.22M | 11.06M |
| Gross Profit | 23.17M | 34.99M | 33.79M | 25.03M | 28.97M |
| Gross Profit Ratio | 62.68% | 62.79% | 66.01% | 63.77% | 72.37% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 6.41M | 5.07M | 4.60M | 3.54M | 4.65M |
| SG&A | 6.41M | 5.07M | 4.60M | 3.54M | 4.65M |
| Other Expenses | 16.76M | 2.21M | 1.94M | 2.20M | 946.00K |
| Operating Expenses | 23.17M | 31.18M | 32.12M | 25.64M | 31.21M |
| Cost & Expenses | 52.50M | 51.91M | 49.52M | 39.85M | 42.28M |
| Interest Income | 344.21K | 63.91K | 4.65K | 5.97K | 2.23K |
| Interest Expense | 71.00K | 48.00K | 406.00K | 868.00K | 828.00K |
| Depreciation & Amortization | 1.88M | 1.80M | 1.75M | 1.65M | 569.66K |
| EBITDA | -12.94M | 5.67M | 1.99M | 1.04M | -1.67M |
| EBITDA Ratio | -35.01% | 10.18% | 6.68% | 2.66% | -4.18% |
| Operating Income | -15.10M | 5.67M | 1.67M | -609.42K | -2.24M |
| Operating Income Ratio | -40.85% | 10.17% | 3.27% | -1.55% | -5.60% |
| Total Other Income/Expenses | 253.71K | 15.94K | -1.42M | -863.03K | -827.77K |
| Income Before Tax | -14.85M | 3.83M | 248.26K | -1.48M | -3.07M |
| Income Before Tax Ratio | -40.16% | 6.87% | 0.49% | -3.77% | -7.67% |
| Income Tax Expense | -3.54M | 1.14M | 993.53K | -294.73K | -678.00K |
| Net Income | -11.30M | 2.69M | -745.24K | -1.18M | -2.39M |
| Net Income Ratio | -30.58% | 4.82% | -1.46% | -3.01% | -5.98% |
| EPS | -1.33 | 0.32 | -0.09 | -0.14 | -0.28 |
| EPS Diluted | -1.33 | 0.32 | -0.09 | -0.14 | -0.28 |
| Weighted Avg Shares Out | 8.50M | 8.50M | 8.50M | 8.50M | 8.50M |
| Weighted Avg Shares Out (Dil) | 8.50M | 8.50M | 8.50M | 8.50M | 8.50M |
Source: https://incomestatements.info
Category: Stock Reports